Navigation Links
Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
Date:1/26/2012

PARSIPPANY, N.J., Jan. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc.- Florida has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Watson's generic versions of Mallinckrodt's Exalgo® (Hydromorphone Hydrochloride Extended-Release ) tablets.  Mallinckrodt filed its lawsuit on December 10, 2010 in the United States District Court for the District of New Jersey following Watson's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its product in the 8 mg, 12 mg, and 16 mg dosage strengths.
Under terms of the settlement agreement, Mallinckrodt has granted Watson a royalty-free license to U.S. patents relating to Exalgo®.  Watson will have the right to launch its bioequivalent products on November 15, 2013.  Other details of the settlement were not disclosed.

Based on available information, Watson believes it may be a "first applicant" to file an ANDA for the generic version of Exalgo® and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-h
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... Columbia, March 26, 2015  OncoGenex Pharmaceuticals, Inc. ... of clinical developments and announced fourth quarter and ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... agreed to negotiate the termination of their collaboration ... the final termination agreement are ongoing. , ...
(Date:3/26/2015)... S.C. , March 26, 2015 ... told by their existing PACS vendor their system ... (CMH) determined that they needed a better structured ... Hospital selected Avreo interWORKS due to its interface ... modern meaningful use standards through to the hospital,s ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
... MORRISTOWN, N.J., Jan. 3, 2012 Actavis Group, ... it has begun shipping Clobetasol Propionate Shampoo and ... ® Shampoo and Clobex ® Topical ... has granted Actavis a 180-day marketing exclusivity. ...
... Jan. 3, 2012  Cyberonics, Inc. (NASDAQ: CYBX ) ... (FDA) has approved its re-designed AspireHC (High Capacity) generator, which ... 2011. "We are pleased that the FDA was ... us to resume our limited commercial release of the AspireHC ...
Cached Medicine Technology:Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion 2Cyberonics Announces FDA Approval of Re-Designed AspireHC™ Generator for VNS Therapy 2Cyberonics Announces FDA Approval of Re-Designed AspireHC™ Generator for VNS Therapy 3
(Date:3/26/2015)... March 26, 2015 Let’s not lose ... Fresh produce are today’s traffic magnets. Three out of ... because of their produce department, according to a Packaged ... as people are looking to add more fruits and ... Produce Manager® Day is April 2. As featured in ...
(Date:3/26/2015)... Alliance Healthcare Foundation (AHF), a nonprofit ... the poor and underserved in San Diego and Imperial ... $1 million award, the Innovation Initiative (i2). , ... round of our Innovation Initiative Award,” AHF Executive Director ... creative and ambitious projects in the past with this ...
(Date:3/26/2015)... UC Davis will establish a prestigious, leading-edge center ... A Silvio O. Conte Center for Basic or Translational ... the United States. , The center will be funded ... of Mental Health, which will allow UC Davis’ Conte ... of schizophrenia may be dysregulation of immune molecules that ...
(Date:3/26/2015)... March 26, 2015 Florida Hospital teamed up ... For Your Health campaign and live Dr. Oz event, which ... March 21st. More than a thousand people came out to ... living. , The world renowned cardiothoracic surgeon and Emmy ... Linda Hurtado and a panel of experts for the live ...
(Date:3/26/2015)... New York (PRWEB) March 26, 2015 ... to move forward nationwide, with the issuance of ... in Pennsylvania and Louisiana. According to an Order ... multidistrict litigation established for Xarelto injury claims in ... will now allow plaintiffs to file cases directly ...
Breaking Medicine News(10 mins):Health News:Applications Open for $1M Innovation Initiative Award from Alliance Healthcare Foundation 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 3Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 4Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 2Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 3Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3
... , DENVER, July 14 Clinic Service Corporation (CSC), ... has secured an agreement to be the exclusive provider of medical ... , "This is another key new contract for us," ... and deep roots in the Littleton community. Our goal is to ...
... , , , , ... Hoyer, Chairman Henry Waxman, Chairman Charles Rangel, Chairman George Miller, Chairman John ... Capitol this afternoon to discuss legislation introduced today by the Tri-Committees on ... Below are the Speaker,s opening remarks and closing statement. A transcript ...
... , FLEMINGTON, N.J., July 14 A new national ... that the H1N1 Swine Flu poses some level of risk for a ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20071204/NYTU133LOGO ... conducted last night by HCD Research using its MediaCurves.com(R) website, and the ...
... , BEDFORD, N.H., July 14 Emerson Ecologics, ... Manager and Dr. Christine Toomasi has been named Professional Services Specialist. ... practitioner customers. , , Dr. ... Services team. Her enthusiasm, industry knowledge and experience in the ...
... , PHOENIX, July 14 Just weeks after the ... The World Egg Bank (TWEB) today announced a new loan program ... , Offered through Kansas-based Home National Bank, the program can ... or the total cost of an in vitro fertilization (IVF) procedure using fresh ...
... , WASHINGTON ., ... of the Congressional Urban Caucus, release d this statement ... the American Affordable Health Choices Act: , ... is the day that health care reform for all Americans begins its ...
Cached Medicine News:Health News:Pelosi Remarks at Press Conference on Introduction of Health Care Legislation 2Health News:Pelosi Remarks at Press Conference on Introduction of Health Care Legislation 3Health News:Physicians' Level of Concern for H1N1 Swine Flu Pandemic Highest Since April 2Health News:Physicians' Level of Concern for H1N1 Swine Flu Pandemic Highest Since April 3Health News:Emerson Ecologics Expands Their Team of Naturopathic Doctors 2Health News:New Fertility Financing for Donated Eggs Fills Void Left by Capital One 2Health News:Urban Caucus Chair Says Healthcare Reform Means You Can Have Your Care and Keep It Too 2
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Sodium in serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: